Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool aims to help blood clot patients choose wisely on blood thinners

NCT ID NCT07659106

Knowledge-focused Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a decision aid for people who have had a first blood clot and must decide whether to stop or continue blood thinners after at least 3 months of treatment. The aid provides balanced information on risks and benefits and helps clarify personal values. Researchers will measure whether it reduces confusion and improves knowledge in 850 participants across 12 Canadian clinics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Patient decision aid (behavioural intervention)
What this could lead to
If successful, this decision aid could help patients and doctors make more informed, values-based choices about blood thinner use after a first blood clot.
What could go wrong
This is a behavioural study, not a drug trial, so it won't directly treat or cure the condition. The aid may not change outcomes like clot recurrence or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 850 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * First episode of objectively confirmed unprovoked or weakly provoked venous thromboembolism (VTE) * Objectively confirmed proximal deep vein thrombosis and/or segmental or greater pulmonary embolism * Completed at least 3 months of therapeutic anticoagulation and currently receiving anticoagulation * Enrollment within 12 months of diagnosis of the index/qualifying VTE event * Able to provide written informed consent * Able to participate in shared decision-making in English or French Exclusion Criteria: * Recurrent unprovoked or weakly provoked VTE I(i.e. multiple unprovoked/weakly provoked VTE) * Index/qualifying VTE is a strongly provoked VTE (e.g., associated with major surgery, major trauma, plaster cast immobilization, or prolonged bed rest) * Index/qualifying VTE associated with a persistent strong provoking risk factor (e.g., active cancer or ongoing immobility) * Women at very low recurrence risk (HERDOO2 score 0-1) * High bleeding risk such that anticoagulation should be discontinued * Requirement for long-term anticoagulation for another indication (e.g., atrial fibrillation) * Prior dedicated long-term anticoagulation Decision Visit regarding anticoagulation duration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deep vein thrombosis (DVT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep vein thrombosis (DVT) Pulmonary embolism Venous thromboembolism (VTE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ottawa Hospital - General Campus

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Institute of McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

  • Sir Mortimer B. Davis Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • University of Calgary

    Calgary, Alberta, T2N 1N4, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, V5Z 1N1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.